Assuming regulatory approval, what role do you foresee for varegacestat (RINGSIDE) in the management of progressive desmoid tumors, particularly in relation to existing systemic treatment options?

Acknowledging the limitations of cross-trial comparisons, hard to overlook the possibility that varegacestat is a more potent GSI reflected in higher RR, better HR, and the higher median decrease in tumor volume. The once-a-day dosing is also likely to be an added attraction. Clearly, the dose adjustments that were needed on the trial will have to be kept in mind as the real-world experience gains ground. In the end, there will be patients who tolerate one GSI better than the other, and there wi...

Once-daily dosing is certainly more attractive from the patient's perspective. Apart from that, I do not foresee many differences in the impact on how we manage desmoid tumors. Since this was also a placebo-controlled trial, there is no way to judge it against nirogacestat.